Filing Details

Accession Number:
0001144204-12-065878
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-11-30 18:00:31
Reporting Period:
2012-11-28
Filing Date:
2012-11-30
Accepted Time:
2012-11-30 18:00:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
868278 Prophase Labs Inc. PRPH Pharmaceutical Preparations (2834) 232577138
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1459632 S Mark Leventhal 621 N. Shady Retreat Road
Doylestown PA 18901
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0005 Acquisiton 2012-11-28 47,300 $1.42 47,300 No 4 P Indirect By Mark S & Donna R Leventhal Family Foundation Inc.
Common Stock, Par Value $0.0005 Acquisiton 2012-11-29 102,700 $1.60 150,000 No 4 P Indirect By Mark S & Donna R Leventhal Family Foundation Inc.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Mark S & Donna R Leventhal Family Foundation Inc.
No 4 P Indirect By Mark S & Donna R Leventhal Family Foundation Inc.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.0005 290,195 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4193 to $1.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. The reporting person and his wife control the Mark S & Donna R Leventhal Family Foundation Inc., a charitable foundation. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.599 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.